Add
GNTA.OB to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| GNTA.OB > SEC Filings for GNTA.OB > Form 8-K on 29-Apr-2009 | All Recent SEC Filings |
29-Apr-2009
Other Events, Financial Statements and Exhibits
On April 7, 2009, Genta Incorporated, (the Company), announced a final progress update on the Company's Phase 3 trial of Genasense® (oblimersen sodium) Injection, Genta's lead oncology product, in patients with advanced melanoma. The trial recently completed accrual, and final data on progression-free survival (PFS) - a co-primary endpoint in this trial -- are anticipated in the Fall of 2009.
AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is
intended to support global registration of Genasense for patients with advanced
melanoma. The study is designed to confirm certain safety and efficacy results
from Genta's prior randomized trial of Genasense combined with dacarbazine
(DTIC) in patients who have not previously received chemotherapy and who are
identified by a biomarker (low-normal levels of lactate dehydrogenase
[LDH]). The co-primary endpoints of AGENDA are PFS and overall survival.
(d) Exhibits.
Exhibit Number Description
99.1 Press Release of the Company dated April 29, 2009
|
|
|